A tool to predict risks in early stage lung cancers
CHIRP Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers
This study is testing a new computer tool called CHiRP that helps doctors figure out which patients with early-stage non-small cell lung cancer might not need extra chemotherapy after surgery, so they can avoid unnecessary treatment and side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10541900 on NIH RePORTER |
What this research studies
This research focuses on developing a computerized tool called CHiRP that helps identify which patients with early stage non-small cell lung cancer (NSCLC) are at low risk for disease recurrence. By analyzing histologic data, the tool aims to determine whether patients will benefit from additional chemotherapy after surgery. This could prevent unnecessary treatment and its associated side effects for patients who are unlikely to gain any benefit. The approach combines advanced algorithms and biological assays to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with early stage non-small cell lung cancer (stage I and II).
Not a fit: Patients with advanced stage lung cancer or those who do not have non-small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help patients avoid unnecessary chemotherapy, reducing side effects and healthcare costs.
How similar studies have performed: Previous research has shown promise in using predictive tools for cancer treatment, but this specific approach with CHiRP is novel.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Madabhushi, Anant — Emory University
- Study coordinator: Madabhushi, Anant
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.